ストックスクリーナーアプリを入手
2.23
0.90%
0.02
アフターアワーズ：
2.23
前日終値:
$2.21
開ける：
$2.22
24時間の取引高:
91,558
Relative Volume:
0.63
時価総額：
$38.92M
収益：
$411.00K
当期純損益:
$-4.85M
株価収益率:
-1.9735
EPS:
-1.13
ネットキャッシュフロー:
$-4.88M
1週間 パフォーマンス:
-0.45%
1か月 パフォーマンス:
+1.36%
6か月 パフォーマンス:
-22.57%
1年 パフォーマンス:
+71.54%
1日の値動き範囲:
$2.15
$2.24
1週間の範囲:
$2.00
$2.31
52週間の値動き範囲:
$1.20
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
名前
Lexaria Bioscience Corp
セクター
電話
250-765-6424
住所
100 - 740 MCCURDY ROAD, KELOWNA
LEXX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
2.23 | 38.92M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexaria Bioscience Corp (LEXX) 最新ニュース
Lexaria's Registered GLP-1 Study #4 Begins Dosing - Yahoo Finance
Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com South Africa
Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com
Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan
Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance
Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance
LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com
LEXX: Phase I Start Imminent - Yahoo Finance
Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World
LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com
Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com
Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria
Lexaria Bioscience CEO buys $118,391 in shares - Investing.com
Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World
Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com
LEXXW (Lexaria Bioscience) 3-Year Revenue Growth Rate : -39.20% (As of Aug. 2024) - GuruFocus.com
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Markets Insider
Lexaria's DehydraTECH Breakthrough: Fox Business to Spotlight Drug Delivery Innovation | LEXX Stock News - StockTitan
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SEC Form DEF 14A filed by Lexaria Bioscience Corp. - Quantisnow
Form DEF 14A Lexaria Bioscience Corp. For: Jan 14 - StreetInsider.com
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments | LEXXW Stock News - StockTitan
Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments - StockTitan
Lexaria Bioscience holds buy rating, steady stock target on positive study results - Investing.com Canada
Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug | LEXXW Stock News - StockTitan
Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug - StockTitan
Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study - TipRanks
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - JCN Newswire
Lexaria's DehydraTECH Outperforms Rybelsus in Diabetes Study with 11.5% Better Weight Loss - StockTitan
LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan
Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com
Lexaria commences unique drug distribution study - Investing.com
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - WICZ
Lexaria Signs Contract for New DehydraTECH GLP-1 Biodistribution Study - ACN Newswire
Lexaria Launches Groundbreaking Semaglutide Study vs. Rybelsus Formulation - StockTitan
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Yahoo Finance
Lexaria Bioscience Corp. (LEXX) Quarterly 10-Q Report - Quartzy
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Yahoo Finance
Lexaria Positions DehydraTECH Platform in Booming $471B GLP-1 Drug Market - StockTitan
Lexaria reports promising blood sugar control in animal study - Investing.com India
Lexaria reports promising blood sugar control in animal study By Investing.com - Investing.com Australia
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria reports advances in weight loss drug study - Investing.com India
Lexaria reports advances in weight loss drug study By Investing.com - Investing.com UK
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study - StockTitan
Lexaria Bioscience : Corporate Presentation - Marketscreener.com
Lexaria Bioscience Corp. sets date for combined annual and special meeting - Investing.com India
Lexaria Bioscience Corp (LEXX) 財務データ
収益
当期純利益
現金流量
EPS
Lexaria Bioscience Corp (LEXX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
| TURKEL CATHERINE C. | Director |
Aug 12 '24 |
Buy |
3.13 |
1,600 |
5,008 |
3,100 |
| Carle Vanessa | Secretary |
Jul 31 '24 |
Sale |
4.00 |
2,567 |
10,268 |
0 |
| Carle Vanessa | Secretary |
May 14 '24 |
Option Exercise |
1.15 |
2,500 |
2,875 |
2,567 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):